Bradley Canino
Stock Analyst at Stifel
(1.78)
# 3,139
Out of 4,761 analysts
91
Total ratings
28.57%
Success rate
-7.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $17.77 | +187.00% | 6 | Feb 12, 2025 | |
| JANX Janux Therapeutics | Maintains: Buy | $70 → $115 | $36.01 | +219.36% | 2 | Dec 3, 2024 | |
| AFMD Affimed | Maintains: Hold | $5 → $4 | $1.04 | +284.62% | 5 | Nov 15, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $41 | $16.38 | +150.31% | 5 | Oct 14, 2024 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $8.25 | +130.30% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $13.15 | +219.39% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $22.12 | +80.83% | 4 | Sep 25, 2024 | |
| RLAY Relay Therapeutics | Reiterates: Buy | $28 | $3.92 | +614.29% | 4 | Sep 16, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $115 → $135 | $79.49 | +69.83% | 4 | Sep 16, 2024 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $20 | $7.68 | +160.42% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $5 → $3 | $1.12 | +167.86% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.28 | +681.25% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.32 | +331.03% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $47.37 | +108.99% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $3.01 | +365.12% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $9.03 | +342.97% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $130 | $92.25 | +40.92% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $36.81 | +49.42% | 4 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $10 | $2.16 | +362.96% | 4 | Jun 30, 2023 |
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $17.77
Upside: +187.00%
Janux Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $70 → $115
Current: $36.01
Upside: +219.36%
Affimed
Nov 15, 2024
Maintains: Hold
Price Target: $5 → $4
Current: $1.04
Upside: +284.62%
Syndax Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $40 → $41
Current: $16.38
Upside: +150.31%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $8.25
Upside: +130.30%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $13.15
Upside: +219.39%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $22.12
Upside: +80.83%
Relay Therapeutics
Sep 16, 2024
Reiterates: Buy
Price Target: $28
Current: $3.92
Upside: +614.29%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $79.49
Upside: +69.83%
ORIC Pharmaceuticals
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $7.68
Upside: +160.42%
Aug 9, 2024
Reiterates: Hold
Price Target: $5 → $3
Current: $1.12
Upside: +167.86%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.28
Upside: +681.25%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.32
Upside: +331.03%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $47.37
Upside: +108.99%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $3.01
Upside: +365.12%
May 1, 2024
Initiates: Buy
Price Target: $40
Current: $9.03
Upside: +342.97%
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $92.25
Upside: +40.92%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $36.81
Upside: +49.42%
Jun 30, 2023
Upgrades: Buy
Price Target: $2 → $10
Current: $2.16
Upside: +362.96%